CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-04). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 2204 · Search date 2026-08-04 · Methodology v0.6

Ten-year PM2.5 exposure,
does it really help with Higher incidence of dementia?

30-Second Summary
C
Evidence Grade C · 56 · Safety warning
All-cause dementia was associated with PM2.5, but personal exposure was not directly measured
Long-term PM2.5 exposure is associated with the serious outcome of incident dementia. This observational study alone cannot identify the cause of dementia in an individual.
What the
research shows
The grade is C with 56 points. The ACT cohort recorded 1,136 all-cause dementia cases over 41,329 person-years among 4,166 participants. Each 1-microgram/m3 higher address-based 10-year PM2.5 average was associated with HR 1.16 (95% CI 1.03 to 1.31). Alzheimer dementia alone was null at 1.11 (0.97 to 1.27), so the result is not established across every dementia type.
What the
ads claim
An address-level association does not establish that a purifier or supplement prevents dementia. Product-specific reduction in long-term personal exposure and dementia events would require separate evidence.
*

Useful facts when choosing a product

  • Mean 10-year PM2.5 was 10.1 plus or minus 2.9 micrograms/m3, estimated by address rather than personal monitoring.
  • The analysis included 4,166 people, 41,329 person-years, and 1,136 dementia events.
  • All-cause dementia was positive, whereas the Alzheimer-only interval included one.
Gap Measurement · Verdict 2204 · C 56
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

ACT screened dementia-free older adults every two years and used standardized expert consensus diagnosis. A 10-year moving average from a spatiotemporal model was linked to address histories from 1978 to 2018, so moves were incorporated and 97% of addresses had exact geocoding. Personal and indoor concentrations were not measured. Models adjusted for sex, education, race, neighborhood median income, and calendar time, but the extent of self-reported covariates was not verified. Residual confounding from occupation, population density, indoor filtration, commuting, noise, and greenspace remained; income was represented only by a neighborhood median. Lag analyses were less precise, and monotonic concentration-response data were not verified. Public and academic support and relevant consulting relationships were disclosed.

02

Why this is classified as C (56)

Consensus all-cause dementia events are strong, but the null Alzheimer-only result and overlapping exposure and confounding defects give C with 56 points.

Counterpoint. The all-cause dementia result should not be expanded to Alzheimer disease alone or to certain individual causation.

Rejudgment record. Cross-check applied — Accepted the consensus all-cause dementia association while accounting for the null Alzheimer-only result, absent personal and indoor exposure, and residual occupation and population-density confounding

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (C).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Higher all-cause dementia incidenceBThe HR was 1.16 per 1 microgram/m3 and its interval excluded one.
Higher Alzheimer dementia incidenceDThe 1.11 estimate had a 95% confidence interval of 0.97 to 1.27, including one.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Population-based prospective cohort1,136Public and academic support including NIEHS, NIA, and the University of WashingtonConsensus-adjudicated all-cause and Alzheimer dementia incidencePer 1 microgram/m3: all-cause dementia HR 1.16 (1.03-1.31); Alzheimer dementia HR 1.11 (0.97-1.27).Key direct dementia-event evidence
Study 2Population-based administrative cohort257,816Canadian public research supportNew dementia identified in administrative dataHR 1.04 (1.03-1.05) per interquartile-range increase in PM2.5.Large supportive evidence in the same direction
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-04).

Shaffer RM, Blanco MN, Li G, et al. Fine Particulate Matter and Dementia Incidence in the Adult Changes in Thought Study. Environ Health Perspect. 2021;129(8):087001. PMID: 34347531. DOI: 10.1289/EHP9018.
checked
Chen H, Kwong JC, Copes R, et al. Exposure to ambient air pollution and the incidence of dementia: A population-based cohort study. Environ Int. 2017;108:271-277. PMID: 28917207. DOI: 10.1016/j.envint.2017.08.020.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-04 · Corrections: none

Cite this verdict

Ten-year PM2.5 exposure x incident dementia Evidence Grade C card
[Chamgap] Ten-year PM2.5 exposure x incident dementia — Evidence Grade C·56. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/long-term-pm25-incident-dementia/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.